Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15352972 | 0.98 | KDM4E (0.47) | CYP2C9ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL15353192 | 0.98 | KDM4E (0.47) | CYP2C9ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL2105728 | 0.95 | CYP2C9 (0.48) | CYP2C9ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL2104687 | 0.88 | CYP2C9 (0.52) | CYP2C9ALDH1A1CYP1A2CYP2C19KMT2A | |
| SCHEMBL7690977 | 0.86 | PPARG (0.40) | CYP2C9ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL28088543 | 0.83 | CYP2C9 (0.47) | CYP2C9ALDH1A1CYP1A2CYP2C19KMT2A | |
| SCHEMBL6680895 | 0.83 | ALDH1A1 (0.52) | CYP2C9ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL28108218 | 0.83 | SLC6A4 (0.51) | CYP2C9ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL6684956 | 0.82 | ALDH1A1 (0.50) | CYP2C9ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL6679062 | 0.82 | ALDH1A1 (0.50) | CYP2C9ALDH1A1CYP1A2CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3040332-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-9730448-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20160205935-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040332-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | Sumitomo Chemical Company, Limited (JP) | 2016-07-06 | — | — | EP | disclosed |
| EP-2841429-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| WO-2013162072-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2004063169-A1 | HYDROXAMID ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-07-29 | — | — | WO | disclosed |
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| EP-1142880-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1070703-A1 | Cyclobutene derivatives | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| CN-1039321-C | New beta-amino-alpha-hydroxycarboxylic acids and their use | SANKYO CO (JP) | 1998-07-29 | — | — | CN | disclosed |
| CN-1064683-A | New beta-amino-alpha-hydroxycarboxylic acids and uses thereof | SANKYO CO (JP) | 1992-09-23 | — | — | CN | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | CBR3, CYCS, CBR1 | CYP2C9 27/4885ALDH1A1 1594/4885CYP1A2 49/4885 |
| US-20160205935-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, UQCRB, RPS20 | CYP2C9 78/4885ALDH1A1 2181/4885CYP1A2 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.